CBD-Dominant Cannabis Extracts Associated with Better Pain Outcomes Than THC Alone in Older Adults, But Study Design Limits Conclusions

A German registry study of nearly 1,000 propensity-score-matched older adults with chronic pain reports striking differences in tolerability and effectiveness between CBD-dominant extracts and THC/dronabinol, but the observational design cannot rule out confounding, indication bias, or unmeasured differences between groups, making these findings hypothesis-generating rather than practice-changing.

Why This Matters

Chronic pain in older adults remains one of the most pressing unmet needs in clinical medicine, with opioid-related harms disproportionately affecting this population and few well-studied alternatives available. Cannabis-based medicines are increasingly prescribed in this age group, yet head-to-head comparisons of different cannabinoid formulations are essentially absent from the literature. This study represents one of the first efforts to compare CBD-dominant and THC-dominant products in older adults using a validated multidimensional outcomes framework, making its findings immediately relevant to clinicians navigating real-world prescribing decisions even as its design demands cautious interpretation.

Clinical Summary

Managing chronic pain in adults aged 65 and older presents unique pharmacological challenges, including polypharmacy, altered drug metabolism, and heightened sensitivity to psychoactive side effects. This retrospective, propensity-score-matched observational study, published in the Journal of Pain Research in 2026, drew from the German Pain e-Registry to compare 484 older adults receiving CBD-dominant oral cannabis extracts with 484 receiving THC/dronabinol over at least 24 weeks. The mechanistic rationale for the comparison rests on CBD’s distinct pharmacological profile: unlike THC, CBD does not produce intoxication through CB1 receptor agonism and instead modulates pain through multiple pathways including TRPV1 channels, serotonin receptors, and anti-inflammatory mechanisms, potentially offering analgesic benefit with a more favorable side-effect profile in a vulnerable population.

The composite primary endpoint, which required both no adverse-drug-reaction-related discontinuation and clinically meaningful pain improvement, was achieved by 85.7% of CBD-group patients versus 21.9% of THC/dronabinol patients, yielding an odds ratio of 21.5 and a number needed to treat of 2. Adverse drug reactions occurred in 15.5% of the CBD group versus 35.7% of the THC group, with discontinuation rates of 5.6% versus 19.2%. Statistically significant advantages favoring CBD-dominant treatment appeared across all secondary domains. However, these effect sizes are extraordinarily large for a pharmacological comparison and almost certainly reflect residual confounding, indication bias, or unmeasured differences between cohorts that propensity-score matching could not fully address. The authors explicitly frame their findings as exploratory and call for randomized controlled trials before any clinical practice changes are justified.

Dr. Caplan’s Take

This study asks the right question at the right time. Older adults with chronic pain are among the fastest-growing patient populations inquiring about cannabis, and they deserve comparative data rather than anecdotes. The tolerability signal here is clinically plausible: CBD-dominant formulations should, based on what we know about receptor pharmacology, produce fewer psychoactive side effects than pure THC. That part of the story aligns with what I see in practice. But the effectiveness numbers, with an odds ratio above 20, are the kind of result that should trigger skepticism rather than celebration. When an observational study produces effect sizes that would be remarkable for a randomized trial, the most likely explanation involves the design, not the drug.

In my practice, I already favor CBD-dominant or balanced formulations as a starting point for older adults, primarily because of tolerability considerations and the lower risk of cognitive side effects. This study reinforces that instinct without changing my approach. I would not cite these specific effect sizes to patients, but I do use the general principle: for older adults concerned about psychoactive effects, CBD-dominant products are a reasonable place to start, with careful dose titration and ongoing monitoring. We need a proper randomized trial before anyone should treat these numbers as anything more than a promising signal.

Clinical Perspective

This study occupies an early position in the research arc for comparative cannabinoid pharmacotherapy in geriatric pain. It confirms what smaller case series and mechanistic reasoning have suggested: that CBD-dominant formulations may offer a more favorable therapeutic index in older adults than THC-dominant products. However, it does not establish this conclusively. The propensity-score matching reduces overt confounding but cannot account for the clinical reasoning that drove prescribing decisions in the first place. Physicians who prescribed CBD-dominant extracts may have selected patients with better prognoses, fewer comorbidities not captured in the matching variables, or greater treatment adherence. Until a randomized controlled trial replicates even a fraction of these effect sizes, the evidence does not support preferential formulary placement or guideline-level recommendations favoring one formulation over the other.

From a safety standpoint, clinicians should remain attentive to CBD’s inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, which is especially relevant in the polypharmacy environment typical of older adults. Interactions with anticoagulants, statins, antiepileptics, and certain antihypertensives require proactive monitoring. THC/dronabinol carries its own risks, including cognitive impairment, dizziness, and falls, which are disproportionately consequential in this age group. The actionable recommendation now is straightforward: when initiating cannabinoid therapy in older adults, begin with the lowest effective dose of a CBD-dominant formulation, monitor for drug interactions systematically, and document outcomes using validated instruments to contribute to the evidence base these patients urgently need.

Study at a Glance

What Kind of Evidence Is This

This is a retrospective, non-randomized observational study using propensity-score matching to compare two treatment cohorts drawn from a real-world pain registry. It sits below randomized controlled trials in the evidence hierarchy and generates associations rather than causal estimates. The authors themselves classify their findings as exploratory. The single most important inference constraint is that propensity-score matching, regardless of its statistical sophistication, cannot account for unmeasured confounders that influenced prescribing decisions, meaning the observed differences may reflect patient selection rather than treatment effects.

How This Fits With the Broader Literature

Direct comparative studies of CBD-dominant versus THC-dominant cannabinoid formulations in older adults are virtually nonexistent, making this study one of the first to address the question with a meaningful sample size. The tolerability findings are broadly consistent with smaller observational series and pharmacological expectations: CBD lacks the CB1-mediated psychoactive effects that drive many THC-related adverse events, particularly those most concerning in older adults such as dizziness, confusion, and falls risk. The effectiveness findings, however, exceed what prior cannabinoid trials in mixed-age chronic pain populations have demonstrated, where effect sizes are typically modest. Studies such as the Stockings et al. (2018) systematic review of cannabinoids for chronic pain found only moderate-quality evidence of small-to-modest analgesic effects. The magnitude of advantage reported here for CBD-dominant products is far larger than anything in the existing literature, which reinforces the likelihood of residual confounding rather than a genuinely transformative treatment difference.

Common Misreadings

The most likely overinterpretation is treating the odds ratio of 21.5 as evidence that CBD-dominant cannabis is roughly 20 times more effective than THC for pain in older adults. This reading fundamentally mischaracterizes what an observational study can demonstrate. The effect size reflects not only any true treatment difference but also every unmeasured variable that differed between the groups, including prescriber selection, patient expectations, adherence patterns, and comorbidity profiles not captured by the matching algorithm. A second common misreading would be to dismiss THC/dronabinol entirely, when in fact both groups showed meaningful improvement from baseline, suggesting that THC-based products retain a role for appropriately selected patients.

Bottom Line

This registry study provides the first large-scale comparative signal suggesting that CBD-dominant cannabis extracts may offer better tolerability and pain outcomes than THC/dronabinol in older adults. However, the observational design, extraordinary effect sizes, and potential for unmeasured confounding mean these findings are hypothesis-generating only. They support prioritizing CBD-dominant formulations for tolerability-focused clinical reasoning but do not constitute evidence sufficient to change guidelines or prescribing standards without randomized trial confirmation.

Frequently Asked Questions

Does this study prove that CBD is better than THC for pain relief in older adults?

No. Because patients were not randomly assigned to treatments, the observed differences may reflect characteristics of the patients rather than the medications themselves. Physicians may have prescribed CBD-dominant products to patients they expected would do better, or patients choosing those products may have differed in ways the study could not measure. Only a randomized controlled trial can establish whether one formulation truly outperforms the other.

Why are the reported effect sizes considered suspiciously large?

An odds ratio of 21.5 would be extraordinary even in a well-controlled randomized trial comparing an active drug to placebo. In pharmacological comparisons between two active treatments, effect sizes of this magnitude are almost never attributable solely to the drug difference. When observational studies produce such results, the most parsimonious explanation is that unmeasured differences between the patient groups are inflating the apparent treatment effect.

Should I ask my doctor to switch me from THC to CBD based on this study?

This study alone is not sufficient reason to change your treatment. If you are currently using a THC-based product and experiencing good symptom control without problematic side effects, there is no evidence-based reason to switch. If you are experiencing side effects such as dizziness, confusion, or sedation, discussing a CBD-dominant alternative with your physician is reasonable and was already a sensible conversation before this study was published.

Are there specific drug interactions older adults should watch for with CBD-dominant products?

Yes. CBD inhibits several liver enzymes involved in drug metabolism, particularly CYP3A4 and CYP2C19. This means it can increase blood levels of commonly prescribed medications including certain blood thinners like warfarin, cholesterol-lowering statins, some blood pressure medications, and anti-seizure drugs. Older adults taking multiple medications should have their prescribing clinician review potential interactions before starting any CBD-containing product, and ongoing monitoring of affected drug levels may be necessary.

What would a definitive study on this question look like?

A properly designed randomized controlled trial would randomly assign older adults with chronic pain to receive either a CBD-dominant extract or THC/dronabinol, with neither patients nor clinicians knowing which treatment was assigned (double-blinding). It would follow patients for a clinically

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care